Sikmarson @Sikmarson Twitter profile

Last Seen Profiles

@guidopensieri

@Hackspetten031

@fatecolossal

@lkjewqmn

@MerenImson79940

@Sinistrosie

@nadiatodres

@diviniaturgy

@pfeIbma3Mcqna26

@ank_09at

@euvitorsouzza

@wthwithu03

@h6ZtmUnoiV82V3

@conniefracasada

@cutumochi

@GondweMaxmillan

@lady_R_40

@weerapunpandit1

@MahamedMawsi

@RTslavePuppy

@DiegoRafeal3737

@EgyptandMike

@MikaPikaZo

@SAKASAKAmax

@miiraonthego

@rikorisu88

@Sopra_il_fiume

@BlazedRobin

@izzubaik

@penyukastw21

@MichelDelSent

@freri_l

@DelphaNewl87945

@IJNBBMusashi

@Factsonfilm

@ctrent

Sikmarson

@Sikmarson

10 years

$ARIA 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Sep 04 - Sep 07, 2014 http://t.co/htjuYm3g5h

0

4

Sikmarson

@Sikmarson

2 years

@X__Anderson §kilt

0

2

Sikmarson

@Sikmarson

6 years

$CALA Scientists show that drugs targeting tumor metabolism will not stop natural killer cells via @medical_xpress

Scientists show that drugs targeting tumor metabolism will not stop natural killer cells

Scientists have just made an important discovery as to how cancer-targeting 'Natural Killer' (NK) cells are fuelled in the body, which has significant implications for related therapies. They found...

medicalxpress.com

0

1

3

Sikmarson

@Sikmarson

5 years

$CALA

Fabio Schutz

@FabioSchutz78

5 years

Dr. Funda Meroc-Bernstam presented the results of Phase 1 trial with CB-839, a glutaminase inhibitor, plus cabozantinib in pre-treated mRCC patients shows promising results, and paving the way for the phase 2 trial CANTATA. #GU19

0

11

16

0

1

Sikmarson

@Sikmarson

5 years

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) .. One hundred percent of evaluable patients experienced tumor shrinkage and disease control ..

0

1

0

Sikmarson

@Sikmarson

5 years

@xrptrent @WillyWonkaXRP @CoryTV looks like Trudeau...

0

1

Sikmarson

@Sikmarson

10 years

$ARIA will present an update from the ongoing Phase 1/2 clinical trial of AP26113 at the 2014 ESMO annual meeting. (Sep 26 to 30, 2014)

0

1

Sikmarson

@Sikmarson

10 years

$ARIA will present an update from the ongoing Phase 1/2 clinical trial of AP26113 at the 2014 ESMO annual meeting. (Sep 26 to 30, 2014)

0

1

Sikmarson

@Sikmarson

10 years

$ARIA Institutional ownership now 64.52%, last week at 58.74%.

0

1

Sikmarson

@Sikmarson

3 years

@BoxersPandoras @ParallelFi @MoonbeamNetwork I took this ref bonus code, thank you! If someone want to use mine(thanks a lot!) 0x4c851861b9c0e43a906b2360c9875ae1d3fa849b43cbbea3d179abb5fd53a604

0

1